ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 21 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Lords Mark Industries Investor Presentation: Key Takeaways

H1 FY27 investor deck discloses no revenue, PAT or EBITDA figures. Narrative covers MedTech (IVD, Renalyx dialysis), a ~₹2,000 Cr renewables order book and the 85% Renalyx acquisition.

Highlights
MarginsCompany-estimated gross margins: ~62% IVD, ~45% MedTech, ~12% Solar EPC.
Order book~₹2,000 Cr secured; 100 MW+ solar in hand for two years.
Demand visibility₹3,000+ Cr pipeline; ~₹2,000 Cr secured renewables orders.
Management confidencePromotional tone; 'exponential growth' claims unquantified.

Growth

No H1 FY27 revenue or profit growth disclosed. Only market CAGRs cited, e.g. diagnostics 11.6%, genome testing 26.8%.

Outlook

Targets 2,000+ pathology labs, 1,000 Renal Care Units by March 2028; FY27 FPO, FY28 demerger planned. No growth guidance.

Risks

Import dependence, regulatory approvals and execution risk on government-linked pipeline. No risks quantified.

Source

Investor Presentation filed with BSE, NSE: KRATOSENER. Summary written with AI assistance from the document.

Read the document ↗

Lords Mark Industries Ltd: key numbers

Share price
₹68.55
Market cap
₹2,924 Cr
Revenue (annual)
₹684.8 Cr
Net profit (annual)
₹48.59 Cr
P/E (TTM)
28.4×Sector 21.2×
Promoter holding
75.30%-4.54% QoQ
FII holding
1.30%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lords Mark Industries Ltd

All →